Pancreatic cancer, the third deadliest cancer in the U.S., sees its highest survival rates when detected early. Dr. Diane Simeone, Director of UC San Diego Moores Cancer Center, emphasizes prioritizing early detection to save lives.
Symptoms are often vague and appear only in advanced stages, making it a stealthy disease. Red flags include a new diabetes diagnosis coupled with weight loss, or jaundice (yellowing of eyes/skin).
Type 2 diabetes doubles the risk of pancreatic cancer. Chronic inflammation, like that from pancreatitis, also increases risk twofold. A genetic link exists in about 10-20% of cases.
Advocacy for germline testing, a blood test identifying inherited gene defects, is crucial. Genes like BRCA, commonly linked to breast cancer, are also strongly associated with pancreatic cancer. Consistent germline testing is vital, especially for at-risk individuals.
High-risk individuals should consult expertise centers for a multi-disciplinary risk evaluation and individualized management plan, likely including germline testing and regular screening. While no single blood test definitively finds pancreatic cancer, detection methods are improving.
Clinical trials offer promising avenues for early detection and new therapies. The Precede Study aims to significantly improve survival rates through collaboration and research. Treatment options, including surgery, radiation, chemotherapy, and emerging immunotherapies, are most effective when cancer is found early.
A healthy diet, low in processed foods, and regular exercise are also linked to reduced cancer risk and better treatment response. Disparities exist, with underrepresented populations less frequently offered germline testing or informed about screening eligibility.
The five-year survival rate has risen from 5% to 13%, but late-stage diagnosis remains the primary challenge. Patients are urged to advocate for themselves, listen to their bodies, and seek second opinions to drive a focus on early detection.